Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Bioniche Reports Positive Results for Regressin in Treating Bladder Cancer LONDON, Ont., Jan. 16, 1996 -- Bioniche Inc. today reported results from a Phase II/III multi-centre Canadian clinical trial of company's drug Regressin(TM) in the treatment of carcinoma in situ of the bladder, a potentially fatal form of bladder cancer. The interim announcement follows a recent meeting of key investigators which reviewed a preliminary statistical analysis of study results. The conclusion of the investigators was that these results, based on data from 68 patients treated for up to 78 weeks, were extremely positive. Two groups of patients were treated. In patients not previously exposed to any anti-cancer therapy, the positive response rate was 52%. Significantly, patients who had previously failed to respond to BCG, considered to be standard therapy for carcinoma in-situ of the bladder, the response rate was 22%. In addition, tolerance and safety as measured by side effects, were lower with Regressin than those reported in the medical literature for BCG. ``While further data will be released to the medical community by the principal investigator, these results reinforce our belief that Regressin is an efficacious product for the treatment of carcinoma in situ of the bladder and has a margin of safety over other products currently in use,'' said Marvin Skripitsky, Bioniche President and Chief Executive Officer. ``It is particularly important that Regressin appears to be effective in many patients who have failed BCG which is usually used to treat this concerning disease,'' he added. ``We are committed to the filing of a Regressin New Drug Submission in Canada for treatment of C.I.S. Plans for further clinical trials are still under development.'' Bioniche Inc. Inc. is a Canadian biopharmaceutical company based in London, Ontario, engaged in the advancement of healthcare through the research and development of innovative pharmaceuticals. Bioniche recently introduced Cystistat, a unique product for the treatment of interstitial cystitis, a painful bladder condition. Bioniche 's common shares trade on The Toronto Stock Exchange under the symbol BNC. E-mail this page to a friend or colleague! To print, use this version